These novel medications , Semaglutide , represent a significant advancement in treating metabolic dysfunction and possibly associated conditions . These drugs are classified as GLP-1 hormone agonists , meaning they to mimic the natural GLP-1 substance , stimulating glucose secretion and lowering appetite . Despite Retatrutide each operates largely